- Abstract:
-
Ebola viruses (EBOVs) are responsible for repeated outbreaks of fatal infections, including the recent deadly epidemic in West Africa. There are currently no approved therapeutic drugs or vaccines for the disease. EBOV has a membrane envelope decorated by trimers of a glycoprotein (GP, cleaved by furin to form GP1 and GP2 subunits) which is solely responsible for host cell attachment, endosomal entry and membrane fusion. GP is thus a primary target for the development of antiviral drugs. Here...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Accepted manuscript
- Publisher:
- Nature Publishing Group Publisher's website
- Journal:
- Nature Journal website
- Volume:
- 535
- Pages:
- 169-172
- Publication date:
- 2016-06-05
- Acceptance date:
- 2016-05-26
- DOI:
- EISSN:
-
1476-4687
- ISSN:
-
0028-0836
- URN:
-
uuid:bf711b30-68b8-49b9-a6a8-7236cf6de661
- Source identifiers:
-
631690
- Local pid:
- pubs:631690
- Language:
- English
- Copyright holder:
- Fry et al
- Copyright date:
- 2016
- Notes:
- © 2016 Fry et al
Journal article
Toremifene interacts with and destabilizes the Ebola virus glycoprotein.
Actions
Authors
Funding
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record